Clinical research centre located in Melbourne, Australia, has selected LabPas CT to fully automate its Phase I clinical trials
According to Andrew Giddy, CEO of Nucleus Network: "LabPas CT's comprehensive automation of the Phase I laboratory, clinic floor, recruiting, and sample storage enhances our commitment to provide sponsors with operational and service excellence by increasing compliance and speeding trials.
"It also helps position our new 24-bed, state-of-the-art phase I facility as the preeminent clinical research centre in Australia".
John Rosenblum, CEO of Green Mountain Logic, the developer of LabPas CT, added: "Nucleus Network is a very important partner for us.
"It is held in high regard by pharmaceutical and biotechnology sponsors throughout the world, and has very generously agreed to act as a LabPas CT demonstration site for Australia and Asia".
Nucleus Network is one of six highly regarded clinical research organisations in the past year - and one of two international clinics in the last month - to select LabPas CT.
Others include Cedra Clinical Research, Acclaim Pharma Research, Advanced Biomedical Research, Arkansas Clinical Research, and a major US midwest health care facility.
LabPas CT improves margins, decreases liability, and increases clinical capabilities, says its developer.
Nucleus Network conducts clinical research for national and international companies, acts as a drug development advisor to many smaller biotech companies and delivers education in good clinical practice through a collaboration with the Association of Clinical and Research Professionals (ACRP).
Nucleus Network provides a broad range of expertise on clinical research and product development to the global pharmaceutical, biotechnology and medical device industries.
